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Abstract: The immunoexpression of the inhibitor of apoptosis protein survivin has been shown to be a significant 
prognostic factor in various human cancers. Immunohistochemical method was used to examine the expression 
of survivin, Ki67 and Bcl-2 in 20 cases of sinonasal inverted papillomas (IPs), 12 cases of sinonasal squamous 
cell carcinoma (SNCs) and 19 cases of nasal chronic sinusitis as a control. Nuclear immunostaining for survivin 
was observed in 14 of 20 (70%) cases of sinonasal IPs and 10 of 12 (83.4%) cases of SNCs. Apart from nuclear, 
also weak cytoplasmic immunoexpression of survivin was detected in 2 of 20 cases (10%) of sinonasal IP and 
moderate intense staining in 9 of 12 cases (75%) of SNC. There was no immunostaining for survivin in 19 control 
cases. The immunoexpression of survivin, Ki67 and Bcl-2 was significantly higher in SNCs than in sinonasal IPs 
and control group. Moreover, nuclear survivin and Ki67 antigen immunoexpression were significantly higher 
in sinonasal IPs group as compared to control group. There were statistically significant positive correlations 
between nuclear (but not cytoplasmic) immunoexpression of survivin and Ki67 antigen, as well as Bcl-2 oncop-
rotein in both tested tumors. In conclusion, our findings suggest that survivin, Ki67 and Bcl-2 may be involved 
in sinonasal tumorigenesis. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 3, 225–231)
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Introduction 
Cancers arising in the sinonasal cavity and surroun-
ding tissues are extremely rare. It has been estimated 
that the incidence of sinonasal cancers is approxima-
tely 1/500,000 to 1/1000, 000. These epithelial tumors 
occur most commonly in Caucasian race, in the fifth 
and sixth decades of life [1–4]. In comparison to other 
head and neck cancers, no predominant risk factors 
were described. There are some rare occupational 
and industrial exposures which may account for the 
development of these cancers. These include exposure 
to fumes, dusts from wood and leather and exposure 
to cadmium, nickel or chromium dusts and other rare 
minerals. As a consequence of industrial exposure, 
these malignancies appear to occur more commonly 
in males than females (2:1). 
Sinonasal inverted papilloma (IP) is a benign 
epithelial neoplasm that arises from the outlining 
Schneiderian respiratory membrane. It is a rare sino-
nasal tumor accounting for only 0.5–4% of all nasal 
tumors. IPs generate considerable interest, because 
they have features of local invasiveness, tendency 
for recurrence and malignant transformation. The 
incidence of malignant transformation of IPs ranges 
from 2 to 27%. It was reported that nearly 10% of 
IPs are associated with squamous cell carcinoma [5, 
6]. However, the nature and pathogenesis of IPs as 
premalignant lesions are still debated.
Many studies have shown that the occurrence and 
development of malignant tumor are closely related 
to the overexpression of oncogenes and apoptosis 
inhibitory factors. Regulation of apoptosis is finely 
balanced by signaling pathways including apoptosis
-promoting factors such as p53, Bax and caspases, and 
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antiapoptotic factors such as Bcl-2 and MDM2 [7, 8]. 
A group of apoptosis inhibitor molecules, called inhi-
bitor of apoptosis proteins (IAP), constitutes a family 
of evolutionarily conserved apoptosis suppressors; 
one member of the IAP family is survivin [9].
Survivin is a 16.5 kDa protein, also called baculoviral 
inhibitor of apoptosis repeat-containing 5 (BIRC5). It 
contains only one baculovirus IAP repeat and lacks a 
carboxyl-terminal RING finger, which makes survivin 
different from other IAP proteins [9]. Survivin is stron-
gly expressed during embryonic and fetal development. 
It is expressed in human fetal lung, heart, kidney, 
liver and gastrointestinal tract, and may contribute to 
tissue homeostasis and differentiation [10]. Survivin 
is rarely expressed in normal adult tissues except for 
the thymus, placenta and CD34+ stem cells [11]. The 
levels of survivin in normal adult cells are low in resting 
endothelial cells and could be up-regulated on activa-
tion to proliferation [9, 12]. Molecular mechanisms 
of the regulation of survivin expression in cancer are 
not clearly understood, but disruption of the survivin 
induction pathway has resulted in increased apoptosis 
and inhibition of tumor growth [12]. Numerous data 
demonstrate that survivin is highly expressed by the 
most common human neoplasms, including cancers 
of the lung, pancreas, stomach, colon, malignant me-
lanoma, neuroblastoma, genito-urinary, hepatocellular 
and breast cancers, and soft tissue sarcomas [13, 14]. 
Survivin is expressed in human cancer cells at a frequ-
ency of 34–100% [15–17].
Survivin exists in two subcellular compartments — cy-
toplasmic and nuclear and in three splice variants: wild
-type survivin, survivin-2B and survivin delta Ex3. Wild
-type and survivin-2B variants are more often found in 
the cytoplasm, whereas the delta Ex3 is more frequent 
in the nucleus [18]. Survivin plays a pro-mitotic and 
anti-apoptotic role [19, 20]. Survivin is able to inhibit 
factors favorable to apoptosis for example, caspases. 
Survivin can also partially inhibit the cell death induced 
by Fas and Bax [15, 21]. Importantly, it is recognized 
that survivin not only inhibits apoptosis, but also, as a 
component of the chromosomal passenger complex, 
favors cancer cell proliferation [22–24]. During mitosis, 
survivin binds to and stabilizes mitotic spindles [25]. In 
the absence of survivin, cycling cells undergo mitotic 
collapse and caspase 9-mediated apoptosis [26, 27]. 
Upon the completion of mitosis, survivin is efficiently 
removed from the cell, so that cycling cells harvested 
in G1 no longer show survivin expression [28].
Little is known about the distribution of survivin in 
sinonasal lesions and how it correlates with other 
markers of tumorigenesis. Therefore, the objectives of 
this study were to evaluate the immunoexpression of 
survivin, Ki67 and Bcl-2 in cases with sinonasal inver-
ted papillomas and sinonasal carcinomas. Another 
purpose was to find whether the immunoexpression 
of survivin could correlate with the immunoexpression 
of Ki67 and Bcl-2.
Material and methods
Patients. Twenty cases of sinonasal inverted papillomas, 
twelve cases of sinonasal squamous cell carcinomas (GII 
grade) and nineteen cases of chronic sinusitis as a control 
were retrieved from archival material (Chair of Patho-
morphology, Medical University of Lodz, Poland). Tissue 
sections taken from postoperative material were diagnosed 
using a standard hematoxylin and eosin staining and the 
histological diagnoses were established according to the 
current standards [29]. A representative block of formalin 
fixed paraffin-embedded tissue from each case was selected 
and used for the study. The main criteria for patient’s selec-
tion were histopathological similarities within the group and 
the same anatomical localization of lesions. The age range 
for sinonasal inverted papillomas was from 29 to 77 years 
(55.8 ± 12.82, mean and SD), for sinonasal cancer was from 
47 to 71 years (61.1 ± 9.94) and for chronic sinusitis was 
from 20 to 75 (44.8 ± 17.65) years.
Immunohistochemistry. 5 µm sections were cut from blocks 
of formalin fixed paraffin-embedded tissue and mounted on 
microscope slides (SuperFrost Plus, Gerhord Menzel GmbH, 
Braunschweig, Germany), deparaffinized, rehydrated, then 
treated in a microwave oven in a solution of TRS (Target 
Retrieval Solution, Dako, Glostrup, Denmark) for 30 minutes 
(2 × 6 minutes 360W, 2 × 5 180W, 2 × 4 minutes 90W) and 
transferred to distilled water. The endogenous peroxidase 
activity was blocked by incubation in 0.3% hydrogen peroxide 
in distilled water for 30 minutes, and then sections were rinsed 
with Tris-buffered saline (TBS, Dako) and incubated overni-
ght with monoclonal anti-human survivin antibody (dilution 
1:300, Abcam, Cambridge, UK), 30 minutes with mouse mo-
noclonal anti-human antibodies: Ki67 (dilution 1:100, Dako) 
and Bcl-2 (dilution 1:50, Dako). Immunoreactive proteins 
were visualized using EnVision-HRP kit (Dako) according to 
the manufacturer’s protocol. Visualization was performed by 
incubating the sections in a solution of 3,3’-diaminobenzidine 
(Dako). After washing, the sections were counter-stained with 
hematoxylin and coverslipped. For each antibody and for each 
sample negative controls were processed. Negative controls 
were carried out by incubation in the absence of the primary 
antibody and always yielded negative results.
The immunohistochemical expression of cytoplasmic 
survivin was evaluated semiquantitatively. Two independent 
observers scored immunolabeled sections using a scale ran-
ging from 0 to 3 (0 — reaction not detectable, 1 — weak, 
2 — moderate, 3 — intense reaction) in 7–10 high power 
fields. The mean grade was calculated by averaging grades 
assigned by the two observers and the mean approximated 
to the nearest unity.
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Morphometry. The immunohistochemical reactions for 
nuclear survivin, Ki67 and Bcl-2 were analyzed quantitatively 
using computer image analysis system consisting of a PC 
computer equipped with a Pentagram graphic tablet, Indeo 
Fast card (frame grabber, true-color, real-time), produced 
by Indeo (Taipei, Taiwan), and color TV camera Panasonic 
(Tokyo, Japan) coupled with Jenaval Carl Zeiss microscope 
(Carl Zeiss, Jena, Germany). This system was programmed 
(MultiScan 8.08 software, produced by Computer Scanning 
Systems, Warsaw, Poland) to calculate the number of objects 
(semiautomatic function).
The percentage of surviving positive (nuclear), Ki67 po-
sitive cells and Bcl-2 positive epithelial cells were estimated 
by counting 100 cells in five monitor fields (0.029 mm2 each), 
marking immunopositive cells (semiautomatic function), so 
that in each case 500 cells were analyzed. 
Statistical methods. The differences between groups were 
tested using unpaired Student’s t-test preceded by evaluation 
of normality and Levene’s test. The Mann-Whitney U-test 
was used for comparison of means between groups. Correla-
tion coefficients were calculated using Spearman’s method. 
Results were considered statistically significant if p < 0.05.
Results
The immunoexpression of survivin in epithelial tumor 
cells in patients with sinonasal IP and SNC was pre-
dominantly nuclear, although cytoplasmic expression 
was also noted. Nuclear immunoexpression of survivin 
was detected in 14 of 20 cases (70%) with sinonasal 
IPs (Figure 1) and in 10 of 12 cases (83,4%) of SNCs 
(Figure 2). Weak cytoplasmic immunoexpression 
of survivin was detected in 2 of 20 cases (10%) with 
sinonasal IPs and moderate staining in 9 of 12 cases 
(75%) of SNCs (Figure 3). In control patients there 
was no nuclear and no cytoplasmic immunostaining 
for survivin visible.
The results of morphometric analyses of the im-
munoexpression of survivin, Ki67 antigen and Bcl-2 
oncoprotein in patients with sinonasal IP, SNC and 
in control cases are shown in Table 1. The percen-
tages of epithelial tumor cells with nuclear survivin 
immunoexpression and the mean score of cytoplasmic 
immunoexpression of survivin in the SNC group were 
significantly increased as compared to sinonasal IP and 
control cases; in the latter the immunoexpression of 
survivin was entirely negative. The immunoexpresssion 
Table 1. The immunoexpression of survivin, Ki67 antigen, and Bcl-2 oncoprotein in patients with sinonasal IP, sinonasal 
carcinoma (SNC) and controls
Groups Nuclear survivin (%) Cytoplasmic survivin (mean score) Ki67 (%) Bcl-2 (%)
IP (n = 20) 1.08 ± 0.81 0.13 ± 0.11 17.62 ± 6.27 1.76 ± 0.90
SNC (n = 12) 3.75 ± 2.01 1.3 ± 0.9 45.24 ± 9.97 4.18 ± 1.15
Control (n = 19) 0.00 ± 0.00 0.00 ± 0.00 2.85 ± 1.57 1.23 ± 1.03
IP vs. SNC
IP vs. control
SNC vs. control
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p = 0.56 (NS)
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p = 0.09 (NS)
p < 0.001
NS — not significant
Figure 1. Nuclear and cytoplasmic immunoexpression of 
survivin in sinonasal inverted papilloma. Total magnifica-
tion × 200
Figure 2. Nuclear immunoexpression of survivin in sinona-
sal squamous cell carcinoma. Immunohistochemistry. Total 
magnification × 200
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of survivin was also higher in sinonasal IPs group as com-
pared to control group, but only nuclear survivin immu-
noexpression was significantly higher. The percentages 
of epithelial tumor cells with Ki67 immunoreactivity 
(Figures 4, 5) and Bcl-2 positive immunostaining (Figu-
res 6, 7) in the SNC group were significantly increased 
as compared to both sinonasal IPs and control cases. 
The percentages of Ki67 positive epithelial tumor cells 
were also significantly higher in sinonasal IPs group as 
compared with control group. No statistically signifi-
cant difference in Bcl-2 immunoexpression was noted 
between sinonasal IPs and control cases.
The correlations between the immunoexpression 
of survivin and Ki67 antigen and between survivin 
and Bcl-2 oncoprotein in patients with sinonasal IP 
and SNC are presented in Table 2. In the SNC and 
sinonasal IP groups there were statistically significant 
positive correlations between nuclear immunoexpres-
sion of survivin and Ki67 immunoreactivity, as well 
as Bcl-2 oncoprotein positivity, whereas in the SNC 
group the correlations between cytoplasmic immu-
noexpression of survivin and these parameters were 
not significant.
Figure 7. Immunoexpression of Bcl-2 oncoprotein in sino-
nasal squamous cell carcinoma. Total magnification × 200
Figure 4. Immunoexpression of Ki67 in sinonasal inverted 
papilloma. Total magnification × 200
Figure 5. Immunoexpression of Ki67 in sinonasal squamo-
us cell carcinoma. Total magnification × 200
Figure 6. Immunoexpression of Bcl-2 oncoprotein in sino-
nasal inverted papilloma. Total magnification × 400
Figure 3. Cytoplasmic immunoexpression of survivin in sino-
nasal squamous cell carcinoma. Total magnification × 200
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Discussion
Little is known about the biologic and prognostic signi-
ficance of the survivin expression in sinonasal lesions. 
Moreover, data concerning correlation of survivin with 
Ki67 and Bcl-2 proteins in IPs and SNCs are notably 
scanty. Among many publications relevant to survivin 
localization in nuclei and cytoplasm in various cancers, 
part of them showed that the nuclear expression of 
survivin is an unfavorable prognostic marker, where-
as the other proposed an opposing notion [30]. Our 
study showed significantly increased both nuclear and 
cytoplasmic immunoexpression of survivin in SNC pa-
tients as compared to sinonasal IPs and the control ca-
ses. Moreover, nuclear survivin immunoexpression was 
significantly increased in sinonasal IPs in comparison 
with the control group, in which the immunoexpression 
was entirely negative. Similarly to our results, Liang et 
al. [31], demonstrated survivin immunoexpression in 
80% sinonasal squamous cell carcinoma and 73,3% 
of sinonasal IP and showed that survivin expression 
was significantly higher in squamous cell cancers and 
sinonasal IP than in control groups. Liang et al. [31] 
suggested that survivin may play an important role in 
the pathway of progression of sinonasal IP to SNC. In 
the study of cancer and precancerous lesions of oral ca-
vity, it was shown that survivin was expressed in 33% of 
oral precancerous lesions and 94% of oral cancers [32]. 
The authors believed that strong nuclear and cytopla-
smic immunoexpression of survivin is an early event 
during oral carcionogenesis [32]. Grabowski et al. [33] 
showed nuclear expression of survivin in 80% of cases 
of esophageal squamous cell carcinoma. Moreover, 
the survival of patients with nuclear survivin expression 
was significantly lower than that of patients without 
nuclear immunoexpression of survivin. The cytoplasmic 
staining for survivin had no prognostic significance.
In the present study, in all control cases of nasal 
chronic sinusitis the staining for survivin was totally 
negative (no nuclear and no cytoplasmic immunore-
activity). Other investigators also reported differential 
immunoexpression of survivin in cancer and normal 
tissues. For instance, survivin was expressed in 48% 
of sinonasal cancers, but no staining was present in 
normal tissue adjacent to the tumor [34]. Wang et al. 
[35] found survivin immunoexpression in laryngeal 
squamous cell carcinoma, but also did not reveal im-
munoexpression in normal laryngeal mucosa. 
Literature data suggests higher expression of 
survivin (nuclear or cytoplasmic or both), as an 
apoptotic marker which correlates significantly with 
tumor grade, stage, and patient outcome including 
recurrence rate, and disease-free survival rate [12, 
36–38]. Current reports in these research areas are 
inconsistent and propose opposing conclusions regar-
ding the significance and prognostic value of nuclear 
and cytoplasmic immunoexpression of survivin [30]. 
Full understanding of whether the opposite effects 
seen with nuclear vs. cytoplasmic survivin are due to 
the subcellular localization or the differential func-
tions of the splice variants remains to be elucidated. 
Possible explanation for part of these discordant 
results are histopathological differences between 
studied tumors, the low number of studied cases and 
methodological issues. We speculate, that differences 
concerning survivin immunoexpression described in 
our study may indicate that mechanisms responsible 
for the regulation of apoptosis in various tumors are 
different and not fully explored. 
In this study, we have also observed that Bcl-2 
immunoexpression was statistically significantly in-
creased in SNCs in comparison with sinonasal IPs 
and control group. Similar to our results, Liang et al. 
[31] showed significantly higher immunoexpression 
of Bcl-2 in cancers than in normal tissue. Katori et 
al. [39] demonstrated increased immunoexpression 
of Bcl-2 in sinonasal IPs with severe dysplasia and 
invasive cancer compared with control but also with 
sinonasal IP containing mild dysplasia. Our study 
did not reveal statistically significant differences of 
Bcl-2 immunoexpression between sinonasal IPs and 
control group. Surprising results were provided by 
Fan et al. [40] who found no differences regarding 
immunoexpression of Bcl-2 among SNC, sinonasal 
IP and sinonasal IP with dysplasia. In our study the 
high, nuclear survivin immunoexpression in SNC 
and sinonasal IP tissues was correlated with high im-
munoexpression of Bcl-2 oncoprotein. These results 
seem to be consistent with other studies [31, 35, 37, 
41]. In contrary to above-mentioned results, Sun et al. 
[42] did not reveal correlation between survivin and 
Table 2. The correlations between immunoexpression of 
survivin and Ki67 antigen and Bcl-2 oncoprotein in patients 
with sinonasal inverted papilloma (IP) and sinonasal carci-
noma (SNC) 
Correlation between  IP (n = 20) SNC (n = 12)
Nuclear survivin vs. Ki-67 r = 0.57, 
p < 0.009
r = 0.63, 
p < 0.03
Nuclear survivin vs.Bcl-2 r = 0.84, 
p < 0.001
r = 0.72, 
p < 0.009
Cytoplasmic survivin vs. Ki-67 – r = 0.35, 
p = 0.26 (NS)
Cytoplasmic survivin vs. Bcl-2 – r = 0.27, 
p = 0.39 (NS)
NS — not significant
230 Olga Stasikowska-Kanicka et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0032
www.fhc.viamedica.pl
Bcl-2 immunoexpression in 40 cases of laryngeal and 
hypopharyngeal cancers. 
The Ki67 protein is a cellular marker for proli-
feration, present during all active phases of the cell 
cycle. In our study, the immunoexpression of Ki67 
antigen was higher in SNC patients as compared 
to sinonasal IP and control group. This parameter 
was also significantly higher in sinonasal IP group in 
comparison with controls. Similarly to our study, other 
authors also demonstrated higher immunoexpression 
of Ki67 in squamous cell carcinoma and nasal IPs with 
dysplasia, suggesting that a high proliferative rate is 
a characteristic of IP-associated malignant diseases 
[43–47]. Kawasaki et al. [47] postulated survivin as 
the strongest apoptosis inhibitory factor, involved in 
the regulation of cellular proliferation in colon cancer. 
In our study, higher nuclear (but not cytoplasmic) 
survivin immunoexpression was correlated with higher 
Ki67 immunoexpression in both SNC and sinonasal 
IP tissues. To our knowledge, the data concerning 
relationship between these parameters in sinonasal 
lesions are scanty. In model cancer cells, expression 
of the survivin gene was shown to occur exclusively in 
the G2/M phase in a strict cell cycle-regulated manner 
[48], thus potentially explaining a preferential expres-
sion of survivin in poorly differentiated and metastatic 
squamous cell cancers, likely to exhibit high prolifera-
tive potential. At a cellular level, survivin is localized 
to mitotic spindle microtubules of dividing cells [48], 
in a reaction required to preserve apoptosis inhibition. 
In this context, correlations described in our study may 
state logical consequence of the molecular events. 
Based on our results and literature data, we postulate 
that the nuclear survivin immunoexpression can be 
involved in promoting cell proliferation in sinonasal 
tumors, whereas the cytoplasmic survivin immuno-
expression may be associated with clinicopathological 
parameters (not studied in this work). 
In conclusion, our findings may suggest that rela-
tionship between survivin, Ki67 and Bcl-2 could po-
tentially contribute to tumorigenesis in the sinonasal 
region. Profound analysis of molecular mechanism of 
action and subcellular localization of survivin and/or 
its presumptive variants may clarify the function of 
survivin in the regulation of cell viability and cell 
divisions. However, further studies are needed to 
better understand the molecular basis and the role 
of survivin in sinonasal tumorigenesis.
Acknowledgment 
This study was supported by Medical University of 
Lodz, grant 502-03/6-038-01/502-64-022.
References
1. Caplan LS, Hall I, Levine RS et al. Preventable risk factors 
for nasal cancer. Ann Epidemiol. 2000;10:186–191.
2. Weymuller EA, Gal T.J. Neoplasms of the nasal cavity. In: 
Cummings CW, Flint PW, Harker LA et al. (eds.). Otolar-
yngology — Head and Neck Surgery. 4th. Elsevier Mosby. 
Pennsylvania. 2005;1212. 
3. Zimmer LA Carrau RL. Neoplasms of the nose and paranasal 
sinuses. In: Bailey BJ, Johnson JT, Newland SD, eds. Head 
& Neck Surgery — Otolaryngology. 4th. Lippincott, Williams 
& Wilkins. Philadelphia. 2006;417:1480.
4. D’Errico A, Pasian S, Baratti A et al. A case-controlled study 
on occupational risk factors for sino-nasal cancer. Occup 
Environ Med. 2009;66:448–455. 
5. Barnes L. Schneiderian papillomas and nonsalivary glandu-
lar neoplasms of the head and neck. Mod Pathol. 2002;15:
279–297. 
6. Von Buchwald C, Bradley PJ. Risks of malignancy in invert-
ed papilloma of the nose and paranasal sinuses. Curr Opin 
Otolaryngol Head Neck Surg. 2007;15:95–98.
7. Barak Y, Juven T, Haffner R et al. Mdm2 expression is 
induced by wild type p53 activity. Eur Mol Biol Organ J. 
1993;12:461–468.
8. Miyashita T, Krajewski S, Krajewski M et al. Tumor suppres-
sor p53 is a regulator of bcl-2 and bax gene expression in vitro 
and in vivo. Oncogene. 1994;9:1799–1805. 
9. Deveraux QL, Reed JC. IPA family proteins: suppressors of 
apoptosis. Genes Dev. 1999;13:239–252. 
10. Adida C, Crotty PL, McGrath J et al. Developmentally reg-
ulated expression of the novel cancer anti-apoptosis gene 
survivin in human and mouse differentiation. Am J Pathol. 
1998;152:43–49. 
11. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apopto-
sis family member survivin in normal cord blood and bone 
marrow CD34(+) cells by hematopoietic growth factors: 
implication of survivin expression in normal hematopoiesis. 
Blood. 2001;98:2091–2100.
12. Sah NK, Khan Z, Khan GJ et al. Structural, functional 
and therapeutic biology of survivin. Cancer Lett. 2006;244:
164–171.
13. Swana HS, Grossman D, Anthony JN et al. Tumor content of 
the antiapoptosis molecule survivin and recurrence of bladder 
cancer. Lancet. 1999;341:452–453.
14. Yu J, Leung WK, Ebert MPA et al. Increased expression of 
survivin in gastric cancer patients and in first degree relatives. 
Br J Cancer. 2002;87:91–97.
15. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis 
gene, survivin, expressed in cancer and lymphoma. Nat Med. 
1997;3:917–921.
16. Tanaka K, Iwamoto S, Gon G et al. Expression of survivin 
and its relationship to loss of apoptosis in breast carcinomas. 
Clin Cancer Res. 2000;6:127–134.
17. Izava A, Kobayashi D, Nasu S et al. Relevance of c-erbB-2, 
PLU-1 and survivin mRNA expression to diagnostic assess-
ment of breast cancer. Anticancer Res. 2002;22:2965–2969.
18. Rodríguez JA, Span SW, Ferreira CG et al. CRM1-mediated 
nuclear export determines the cytoplasmic localization of the 
antiapoptotic protein Survivin. Exp Cell Res. 2002;275:44–53.
19. Altieri DC. New wirings in the survivin networks. Oncogene. 
2008;27:6276–6284.
20. Mita AC, Mita MM, Nawrocki ST et al. Survivin: key reg-
ulator of mitosis and apoptosis and novel target for cancer 
therapeutics. Clin Cancer Res. 2008;14:5000–5005.
21. Tamm I, Wang Y, Sausville E et al. IAP-family protein sur-
vivin inhibits caspase activity and apoptosis induced by Fas 
231Survivin, Ki67 and Bcl-2 in sinonasal lesions
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0032
www.fhc.viamedica.pl
(CD95), Bax, caspases, and anticancer drugs. Cancer Res. 
1998;58:5315–5320.
22. Uren AG, Wong L, Pakusch M et al. Survivin and the inner 
centromere protein INCENP show similar cell-cycle locali-
zation and gene knockout phenotype. Curr Biol. 2000;10:
1319–1328.
23. Bourhis E, Hymowitz SG, Cochran AG. The mitotic regula-
tor Survivin binds as a monomer to its functional interactor 
Borealin. J Biol Chem. 2007;282:35018–35023. 
24. D’Alessandro N, Poma P, Montalto G. Multifactorial nature 
of hepatocellular carcinoma drug resistance: could plant poly-
phenols be helpful? World J Gastroenterol. 2007;13:2037–2043.
25. Fortugno P, Wall NR, Giodini A et al. Survivin exists in im-
munochemically distinct subcellular pools and is involved in 
spindle microtubule function. J Cell Sci. 2002;115:575–585.
26. O’Connor DS, Grossman D, Plescia J et al. Regulation of 
apoptosis at cell division by p34cdc2 phosphorylation of 
survivin. Proc Natl Acad Sci USA. 2000;97:13103–13107.
27. Yang D, Welm A, Bishop JM. Cell division and cell sur-
vival in the absence of survivin. Proc Natl Acad Sci USA. 
2004;101:15100–15105.
28. Zhao J, Tenev T, Martins LM et al. The ubiquitin-proteasome 
pathway regulates survivin degradation in a cell cycle-depen-
dent manner. J Cell Sci. 2000;113:4363–4371.
29. Barnes L, Everson JW, Reichart P et al. World Health Orga-
nization Classification of Tumours. Pathology and Genetics 
Head and Neck Tumours. IARC Press Lyon. 2005;15–17:28–32.
30. Li F, Yang J, Ramnath N et al. Nuclear or cytoplasmic ex-
pression of survivin: what is the significance? Int J Cancer. 
2005;114:509–512.
31. Liang J, Gao S, Zhang J et al. Expression of Survivin and 
Bcl-2 in sinonasal inverted papilloma. Lin Chung Er Bi Yan 
Hou Tou Jing Wai Ke Za Zhi. 2009;23:933–935.
32. Lo Muzio L, Pannone G, Leonardi R et al. Survivin, a poten-
tial early predictor of tumor progression in the oral mucosa. 
J Dent Res. 2003;82:923–928.
33. Grabowski P, Kühnel T, Mühr-Wilkenshoff F et al. Prognostic 
value of nuclear survivin expression in oesophageal squamous 
cell carcinoma. Br J Cancer. 2003;88:115–119.
34. Zhang Y, Huang D, Yu G. Survivin expression and its rela-
tionship with apoptosis and prognosis in nasal and paranasal 
sinus carcinomas. Acta Otolaryngol. 2005;125:1345-1350. 
35. Wang Y, Kong W, Xiong X et al. The expressions of survivin 
and VEGF in squamous cell carcinoma of larynx and the 
correlation between the two marks. Lin Chuang Er Bi Yan 
Hou Ke Za Zhi. 2005;19:838–841. 
36. Yin W, Chen N, Zhang Y et al. Survivin nuclear labeling index: 
a superior biomarker in superficial urothelial carcinoma of 
human urinary bladder. Mod Pathol. 2006;19:1487–1497. 
37. Ko YH, Roh SY, Won HS et al. Prognostic significance 
of nuclear survivin expression in resected adenoid cys-
tic carcinoma of the head and neck. Head Neck Oncol. 
2010;30:30.
38. Marioni G, Agostini M, Bedin C et al. Survivin and laryngeal 
carcinoma prognosis: nuclear localization and expression of 
splice variants. Histopathology. 2012;61:247–256.
39. Katori H, Nozawa A, Tsukuda M. Cell proliferation, apoptosis, 
and apoptosis inhibition in malignant transformation of sinon-
asal inverted papilloma. Acta Otolaryngol. 2007;127:540–546.
40. Fan GK, Imanaka M, Yang B et al. Characteristics of nasal 
inverted papilloma and its malignant transformation: a study 
of cell proliferation and programmed cell death. Am J Rhinol. 
2006;20:360–363.
41. Zheng YF, Chen ZL, Chen HB et al. Expression of survivin, 
Bcl-2 and p53 during 4-nitro-quinoline 1-oxide-induced rat 
tongue carcinogenesis. Zhonghua Kou Qiang Yi Xue Za Zhi. 
2009;44:168–171. 
42. Sun M, Qin Y. Expression of survivin and its correlation with 
p53 and bcl-2 expression in laryngeal and hypopharyngeal 
cancer. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 
2008;22:346–348,351. 
43. Bura M, Seiwerth S, Vladika I et al. Possible prognostic sig-
nificance of p53 and Ki 67 in inverted sinonasal papilloma. 
Coll Antropol. 2007;31:545–549.
44. Mumbuc S, Karakok M, Baglam T et al. Immunohisto-
chemical analysis of PCNA, Ki67 and p53 in nasal polyposis 
and sinonasal inverted papillomas. J Int Med Res. 2007;35:
237–241.
45. Gunia S, Liebe D, Koch S. Loss of basal cell keratin 14 reflects 
increased risk of recurrence in surgically resected sinonasal 
inverted papilloma. J Clin Pathol. 2008;61:707–712.
46. Hadar T, Shvero J, Yaniv E et al. Human topoisomerase 
II-alpha is highly expressed in sinonasal-inverted papilloma, 
but not in inflammatory polyp. J Cell Mol Med. 2008;12:
1551–1558.
47. Kawasaki H, Toyoda M, Shinohara H et al. Expression of 
survivin correlates with apoptosis, proliferation, and an-
giogenesis during human colorectal tumorigenesis. Cancer. 
2001;91:2026–2032.
48. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and 
mitotic spindle checkpoint by survivin. Nature. 1997;396:
580–584.
Submitted: 4 February, 2013
Accepted after reviews: 14 August, 2013
